Blogs Articles Organizations Biography Jack's Book Contact Information Links

Navigation: SOS Sisson > Life Ethics Blog


Jack Sisson's Life Ethics Blog

We must find new ways through many ethical issues, especially regarding bioethics, medical ethics, and criminal justice. Jack Sisson's 'Life Ethics' blog focuses on numerous areas of concern, including the philosophical and ethical dilemmas surrounding stem-cell research, abortion, medical research, and health care.

 

From USA Today:


Officials at drugmaker Merck & Co. say they will take more time to decide what to do about an experimental blood thinner that gave disappointing results in a second big study.


The study was aimed at preventing repeat heart attacks and strokes in people who had already suffered one or were in danger of one because of hardened arteries in their legs.


The drug, vorapaxar, lowered the risk of those problems but also raised the risk of major bleeding, including dangerous bleeding in the head, which largely canceled out the drug's benefit.


Results of the study were discussed Saturday at an American College of Cardiology conference in Chicago and published by the New England Journal of Medicine.


Merck had hoped vorapaxar would become a blockbuster alternative to Coumadin, sold generically as warfarin and one of the most commonly used heart drugs in the world. It's tough to get warfarin's dose right — too little and a clot can form and cause a heart attack; too much and dangerous bleeding can occur in the stomach or elsewhere in the body.


The company-sponsored study involved more than 26,000 patients in 32 countries. All were given usual heart medicines plus aspirin, and half also received daily vorapaxar pills.


Safety monitors stopped part of the study last year after seeing higher rates of bleeding in the head among people with a history of stroke who were on the experimental drug. The study continued in the rest of the participants.


After three years, about 9% of those given vorapaxar had suffered a heart attack or a stroke or had died from heart-related causes versus more than 10 percent of those not given the drug. Moderate or severe bleeding occurred in about 4% of those on vorapaxar versus just more than 2% of the others, said the study's leader, Dr. David Morrow of Brigham and Women's Hospital in Boston.


Among those with a history of heart attack — two-thirds of study participants — the drug had a net benefit, though, leaving the possibility that Merck might pursue seeking federal approval to sell it for these patients.


However, several experts not connected with the study said the drug's relatively modest benefit and likely high cost would make it a tough sell even if it were allowed on the market.


"This is not a drug that I would put in my personal medicine chest," said Dr. Eduardo Marban of Cedars-Sinai Medical Center in Los Angeles.


Merck officials said they would discuss the results with more scientists before deciding next steps.


Visit USA Today.

Labels: , , , , ,


Brain Pills
Roe v. Wade
Stem Cells
Stem Cell Fight!
Bearing Right
Moral Monkey?
Op-ed
Dave's site
Stem Stall
Screamers
Bush the hypocrite

June 2005   July 2005   August 2005   September 2005   October 2005   December 2005   March 2006   April 2006   May 2006   July 2006   August 2006   September 2006   October 2006   November 2006   January 2007   February 2007   March 2007   April 2007   May 2007   June 2007   July 2007   August 2007   September 2007   October 2007   November 2007   December 2007   January 2008   February 2008   March 2008   March 2009   November 2009   April 2010   October 2010   April 2011   May 2011   January 2012   February 2012   March 2012   April 2012   May 2012   June 2012   November 2012   December 2012   January 2013   February 2013   March 2013   April 2013   May 2013  

only sossisson.com

This page is powered by Blogger. Isn't yours?


  Link to us: Link to us!